Redwood Investments LLC grew its stake in Repligen Co. (NASDAQ:RGEN) by 18.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 190,255 shares of the biotechnology company’s stock after buying an additional 29,666 shares during the quarter. Redwood Investments LLC’s holdings in Repligen were worth $11,240,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently modified their holdings of RGEN. Vanguard Group Inc. boosted its stake in shares of Repligen by 28.4% in the third quarter. Vanguard Group Inc. now owns 3,923,135 shares of the biotechnology company’s stock worth $217,577,000 after acquiring an additional 868,093 shares during the period. Conestoga Capital Advisors LLC raised its stake in shares of Repligen by 1.3% during the 1st quarter. Conestoga Capital Advisors LLC now owns 1,637,430 shares of the biotechnology company’s stock valued at $96,739,000 after buying an additional 21,393 shares during the last quarter. Lord Abbett & CO. LLC raised its stake in shares of Repligen by 286.3% during the 4th quarter. Lord Abbett & CO. LLC now owns 733,291 shares of the biotechnology company’s stock valued at $38,674,000 after buying an additional 543,443 shares during the last quarter. Ardevora Asset Management LLP raised its stake in shares of Repligen by 471.7% during the 4th quarter. Ardevora Asset Management LLP now owns 612,077 shares of the biotechnology company’s stock valued at $32,281,000 after buying an additional 505,020 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of Repligen by 3.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 516,025 shares of the biotechnology company’s stock valued at $28,620,000 after buying an additional 17,176 shares during the last quarter. Institutional investors and hedge funds own 90.89% of the company’s stock.
In other Repligen news, CEO Anthony Hunt sold 7,475 shares of the business’s stock in a transaction that occurred on Thursday, February 28th. The stock was sold at an average price of $59.01, for a total transaction of $441,099.75. Following the completion of the sale, the chief executive officer now directly owns 250,132 shares in the company, valued at approximately $14,760,289.32. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Jon Snodgres sold 1,875 shares of the business’s stock in a transaction that occurred on Thursday, February 28th. The stock was sold at an average price of $58.88, for a total value of $110,400.00. Following the sale, the chief financial officer now owns 26,821 shares of the company’s stock, valued at $1,579,220.48. The disclosure for this sale can be found here. In the last 90 days, insiders sold 48,437 shares of company stock valued at $2,855,032. 1.70% of the stock is owned by company insiders.
Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported $0.28 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.26 by $0.02. Repligen had a return on equity of 6.35% and a net margin of 10.11%. The firm had revenue of $60.63 million during the quarter, compared to analyst estimates of $55.09 million. During the same quarter in the previous year, the business earned $0.17 EPS. Repligen’s revenue for the quarter was up 35.3% compared to the same quarter last year. On average, sell-side analysts expect that Repligen Co. will post 0.94 EPS for the current year.
A number of equities analysts have weighed in on RGEN shares. Zacks Investment Research upgraded Repligen from a “sell” rating to a “hold” rating in a research note on Wednesday, February 27th. BidaskClub lowered Repligen from a “hold” rating to a “sell” rating in a research note on Tuesday, April 9th. Finally, ValuEngine lowered Repligen from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 4th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Repligen has a consensus rating of “Buy” and an average target price of $64.20.
WARNING: This article was posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/05/17/redwood-investments-llc-has-11-24-million-holdings-in-repligen-co-rgen.html.
Repligen Company Profile
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
See Also: What is Forex?
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.